CI

At a glance

ClinicalIndex Comparison Record
Phase 1Unknown· 30 target
Drug / intervention
JYB1907drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05821595
NCT05821595Phase 1Unknown
CompareCT.gov

A Phase I, Multi-center, Open-label Study With Dose-escalation and Multiple Expansion Cohorts to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JYB1907 in Subjects With Advanced Solid Tumors

Jemincare·interventional·Posted Apr 20, 2023·Updated Jun 27, 2023

In Brief

A Phase 1 clinical trial evaluating JYB1907 for Solid Tumor. Targeting 30 participants.

Detailed Summary

A Phase I, Multi-center, Open-label Study with Dose-escalation and Multiple Expansion Cohorts to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JYB1907 in Subjects with Advanced Solid Tumors

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
Countries--
Collaborators--

Timeline

Phase 1UnknownOverdue
202420252026
First PostedApr 20, 2023
Enrollment StartJul 31, 2023
Primary CompletionSep 15, 2024
Study CompletionOct 31, 2024
TodayJul 1, 2026
Enrollment to primary: 1.1 yearsPosted 3.2 years ago

Interventions

JYB1907drug

for injection